联合阻断 TIGIT 和 CD39 或 A2AR 增强 NK-92 细胞对 AML 的细胞毒性

This study aimed to characterize different natural killer (NK) cell phenotypes on bone marrow and peripheral blood cells from acute myeloid leukemia (AML) patients and healthy donors (HDs).

Our data show that CD56 dim CD16 - and CD56 bright CD16 - NK cells represent the predominant NK cell subpopulations in AML, while the CD56 dim CD16 + NK cells are significantly reduced compared to HDs.

Moreover, TIGIT + and PVRIG + cells cluster on the CD56 dim CD16 + subset whereas CD39 + and CD38 + cells do so on CD56 bright CD16 - NK cells in AML.

Furthermore, functional effects of (co-)blockade of TIGIT and CD39 or A2AR on NK cell functionality were analyzed. These experiments revealed that the single blockade of the TIGIT receptor results in an increased NK-92 cell-mediated killing of AML cells in vitro. Combined targeting of CD39 or A2AR significantly augments the anti-TIGIT-mediated lysis of AML cells.

Our data indicate that distinct NK cell subsets in AML exhibit different immunosuppressive patterns (via the TIGIT/PVRIG receptors and the purinergic pathway). In summary, we conclude that TIGIT, CD39, and A2AR constitute relevant inhibitory checkpoints of NK cells in AML patients. A combinatorial blockade synergistically strengthens NK-92 cell-mediated cytotoxicity. As inhibitors of TIGIT, CD39, and A2AR are clinically available, studies on their combined use could be conducted in the near future.